The Autologous matrix-induced Chondrogenesis Market Is Estimated To Increase At A CAGR Of 8.6 Percent During The Forecast Period

AMIC stands for Autologous matrix-induced Chondrogenesis, and it is a biological treatment for articular cartilage injury. AMIC treatment is a multi-step procedure. First, following microfracture surgery, a bi-layer collagen I/III membrane is applied. Second, it reduces cartilage deterioration in the hopes of avoiding or postponing partial or total minor joint replacement surgery (e.g., knee replacement).


In terms of value, the global Autologous matrix-induced Chondrogenesis Market is expected to grow at a CAGR of 8.6% over the forecast period. The need for minimally invasive operations has risen dramatically in recent years. Patients choose minimally invasive operations because of benefits such as fewer post-surgery problems and side effects, a quicker patient recovery time, and a shorter hospital stay. As a result, the autologous matrix-induced chondrocyte is likely to grow in popularity as the demand for minimally invasive operations rises.


Autologous matrix-induced chondrogenesis is a minimally invasive approach that requires only one step. As used in conjunction with micro fracturing, it lowers the cost of micro fracturing compared to other treatment options for chondral and osteochondral lesions. As a result, the cost-effectiveness of the Autologous Matrix-induced Chondrogenesis Market is expected to drive market expansion in the coming years.


Individuals, health care institutions, and social care systems all bear a significant burden from musculoskeletal diseases, with indirect costs dominating. According to the World Health Organization, adults aged 45 and up in the United States and Europe had a greater risk of osteoarthritis, with 14.1 percent of men and 22.8 percent of women suffering from the condition. As a result, the market for autologous matrix-induced chondrogenesis is expected to rise rapidly shortly due to the rising prevalence of bone and joint problems.


Autologous matrix-induced chondrogenesis is a relatively new approach with limited clinical evidence. This prevents doctors and clinicians from using autologous matrix-induced chondrogenesis to treat bone and joint diseases. As a result, the absence of extensive clinical data is anticipated to stifle the Autologous Matrix-induced Chondrogenesis Market in the coming years.


The autologous matrix-induced chondrogenesis market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa, based on region. Increasing sports-related injuries and a growing population are likely to propel North America to the top of the autologous matrix-induced chondrogenesis market during the forecast period.


Biotissue AG, Arthro-Kinetics, JRL Orthopaedic Ltd, B Braun, Melsungen AG, Matricel GmbH, Geistlich Pharma AG, and Zimmer Biomet Holdings are the major key players of Autologous Matrix-induced Chondrogenesis Market.

 


Comments

Popular posts from this blog

Significance of EHealth Software And Services

Radio Frequency Beauty Equipment Market Report | the Demand for the Market Will Drastically Increase in the Future

Broadcast Switchers Market Report | the Demand for the Market Will Drastically Increase in the Future